查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401844

到 2030 年無菌注射劑市場預測：按藥物類型、分子類型、途徑、給藥配銷通路、應用和地區進行的全球分析

Sterile Injectable Market Forecasts to 2030 - Global Analysis By Drug Type, Molecule Type, Route of Administration, Distribution Channel, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球無菌注射劑市場規模為 621 億美元，預計在預測期內複合年成長率為 9.2%，到 2030 年將達到 1,150 億美元。

需要去除活細菌（例如細菌或真菌）的靜脈注射藥物稱為無菌注射劑。這些注射劑可以靜脈注射（IV）、給藥（IM）或給藥（SC）。這些注射劑設計用於直接注射到循環系統或其他無菌身體組織中。它通常在嚴格的無菌加工條件下製備，以確保成品不受微生物污染。

根據美國國家衛生委員會的數據，2016 年，慢性病影響了約 1.33 億美國人，佔全國總人口的 40% 以上。到 2020 年，這一數字預計將增加到約 1.57 億，其中 8,100 萬人患有多種疾病。

對無菌注射劑的偏好日益增加

藥品、生物製藥和疫苗等無菌注射劑對於醫療保健至關重要，特別是對於疾病管理和緊急應變。醫學研究的進步導致了新的注射治療方法的發現和發展。這包括新的醫療干預措施，例如基因療法和細胞療法。這些方面將在整個預測期內推動市場成長。

污染風險

儘管盡可能保持無菌，但在製造、包裝和給藥過程中仍可能發生污染。對患者來說，污染物會導致嚴重的健康問題。此外，有些注射藥物需要特殊的儲存條件，例如冷藏，以保持穩定性。運輸和儲存方面的額外物流障礙限制了市場的成長，特別是在缺乏合適設施的地區。

提高生物利用度

無菌注射劑通常比口服藥物具有更好的生物利用度，因為它們不易受到胃腸道吸收不可預測性的影響。注射藥物通常比口服藥物起效更快。對於治療窗有限或需要固定給藥才能獲得最佳效果的藥物來說，注射劑是有益的，因為可以將更高濃度的藥物直接輸送到循環中。預計這些因素將在預期期間推動市場擴張。

包裝問題

無菌注射劑包裝對於維持產品完整性至關重要。包裝缺陷會導致污染和藥物功效降低。此外，無菌注射劑的製造和品質保證程序可能昂貴且複雜。對人們、衛生系統和製藥公司來說，這代價高昂。因此，這些事情都阻礙了市場的擴張。

COVID-19 的影響：

疫情擾亂了全球供應鏈，導致原料、原料藥成分和包裝材料短缺。這影響了無菌注射劑的分銷和製造。由於勞動力限制、社交距離措施和封鎖，製造業活動受到干擾。勞動力短缺和旅行限制使一些製藥公司難以維持生產水準。

胰島素細分市場預計將成為預測期內最大的市場

預計胰島素領域在預測期內將是最大的。無菌注射胰島素對於糖尿病管理至關重要。透過協助血糖調節，它有助於避免低血糖和高血糖。注射胰島素可以根據患者的特定要求、生活方式和血糖值精確且獨特地調整給藥。不同類型的胰島素有不同的給藥時間和給藥，以客製化治療。

預計癌症產業在預測期內將經歷最高的複合年成長率。

預計癌症產業在預測期內將經歷最高的複合年成長率。藥物治療可以透過無菌注射劑以精確和受控的方式進行。這很重要，因為癌症治療需要精確的給藥，以最大限度地提高治療效果並減少副作用。這在癌症治療中尤其重要，因為可能需要迅速採取行動來阻止癌細胞的生長和擴散。

佔有率最大的地區

由於人口中慢性病和殘疾的盛行率不斷上升，預計北美在預測期內將佔據最大的市場佔有率。該地區發達的醫療基礎設施、知名企業、有吸引力的報銷規則以及在腫瘤學領域的廣泛應用是推動這一市場擴張的因素。此外，美國食品藥物管理局(FDA) 等監管機構對於確保該地區無菌注射藥物的安全性和品質至關重要。

複合年成長率最高的地區：

由於人口中癌症患者數量不斷增加以及政府加強醫療保健部門的投資大幅增加，預計亞太地區在預測期內將保持最高的複合年成長率。在醫療環境中，無菌注射劑對於實施各種治療至關重要，包括特殊藥物、疫苗接種和抗生素。大型製藥企業經常在該地區生產和銷售無菌注射藥物。

免費客製化服務：

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計/預測/複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球無菌注射劑市場：依藥物類型

  • 介紹
  • 細胞激素
  • 單株抗體
  • 胰島素
  • 胜肽激素
  • 血液因素
  • 疫苗
  • 免疫球蛋白
  • 胜肽抗生素
  • 其他類型的藥物

第6章全球無菌注射劑市場：依分子類型

  • 介紹
  • 高分子
  • 低分子

第7章全球無菌注射劑市場：依給藥途徑

  • 介紹
  • 靜脈注射(IV)
  • 給藥（IM）
  • 給藥（SC）

第8章全球無菌注射劑市場：依配銷通路

  • 介紹
  • 醫院藥房
  • 零售藥房
  • 線上藥房

第9章全球無菌注射劑市場：依應用分類

  • 介紹
  • 心血管疾病
  • 肌肉骨骼系統
  • 癌症
  • 感染疾病
  • 糖尿病
  • 中樞神經系統
  • 其他用途

第10章全球無菌注射劑市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • Novartis AG
  • Baxter International Inc.
  • Merck & Co., Inc
  • AstraZeneca plc
  • Johnson & Johnson Services, Inc
  • Gilead Sciences, Inc.
  • JHP Pharmaceuticals
  • Pfizer Inc.
  • Fresenius Kabi Ag
  • CordenPharma
  • Hikma Pharmaceuticals PLC
  • Bryllon LLC
  • Aenova Holding GmbH
  • Vetter Pharma-Fertigung GmbH & Co. KG
  • Catalent Pharma Solutions
Product Code: SMRC24364

According to Stratistics MRC, the Global Sterile Injectable Market is accounted for $62.1 billion in 2023 and is expected to reach $115.0 billion by 2030 growing at a CAGR of 9.2% during the forecast period. Pharmaceuticals that are given intravenously and must be devoid of live germs like bacteria or fungus are referred to as sterile injectables. These injectables can be given intravenously (IV), intramuscularly (IM), or subcutaneously (SC). They are designed to be directly injected into the circulation or other sterile bodily tissues. To guarantee that there is no microbiological contamination in the finished product, they are usually prepared under stringent aseptic processing conditions.

According to the National Health Council, in 2016, chronic diseases affect approximately 133 million Americans, representing more than 40% of the total population of the country. By 2020, that number is projected to grow to an estimated 157 million, with 81 million having multiple conditions.

Market Dynamics:

Driver:

Rise in inclination towards sterile injectables

Sterile injectables, such as medicines, biologics, and vaccinations, are essential to healthcare, particularly for managing diseases and in emergency circumstances. New treatment methods, many of which are injected, have been discovered and developed as a result of advancements in medical research. This covers novel medical interventions such as gene and cell therapy. These are the aspects driving market growth throughout the predicted period.

Restraint:

Risk of contamination

Although sterility is maintained to the best of our ability, contamination can still occur during production, packing, or administration. For patients, contaminants can result in major health problems. Additionally, in order to preserve stability, some injectable medications may need special storage conditions, such refrigeration. Creating additional logistical hurdles for transportation and storage, particularly in areas with poor access to adequate facilities restrains the market growth.

Opportunity:

Increased bioavailability

Sterile injectables frequently offer better bioavailability than oral drugs because they are not susceptible to the unpredictability of gastrointestinal absorption. Medications that are injectable frequently start working faster than those that are oral. For drugs with a limited therapeutic window or those needing a certain dosage for best efficacy, they are beneficial since they deliver larger drug concentrations straight into the circulation. During the anticipated time, these factors will be propelling market expansion.

Threat:

Packaging concerns

Sterilized injectable packaging is essential to preserving the integrity of the product. A breach in the package may result in contamination or a reduction in the medication's effectiveness. Furthermore, the production and quality assurance procedures for sterile injectables can be expensive and complicated. Higher expenses follow for people, healthcare systems, and pharmaceutical corporations alike. Thus, these are the things impeding the market's expansion.

COVID-19 Impact:

The pandemic caused supply chain disruptions on a worldwide scale, resulting in shortages of raw materials, active pharmaceutical ingredients (APIs), and packaging supplies. This has an impact on the distribution and manufacturing of sterile injectables. Manufacturing activities were disrupted by personnel constraints, social distancing measures, and lockdowns. Due to workforce shortages and mobility constraints, several pharmaceutical businesses found it difficult to sustain production levels.

The insulin segment is expected to be the largest during the forecast period

The insulin segment is expected to be the largest during the forecast period. Insulin that is sterile for injection is an essential part of managing diabetes. By assisting in blood glucose regulation, it helps avoid hypo- and hyperglycemia. With injectable insulin, dosage may be precisely and uniquely adjusted for each patient depending on their unique requirements, lifestyle, and blood glucose levels. To customize therapy, a variety of insulin types with different onset and duration characteristics are available.

The cancer segment is expected to have the highest CAGR during the forecast period

The cancer segment is expected to have the highest CAGR during the forecast period. Medication may be administered precisely and under control to sterile injectables. This is important because, in the treatment of cancer, precise dosage is necessary to maximize therapeutic efficacy and reduce adverse effects. This can be especially crucial for cancer therapy, as it may be required to act quickly to stop the growth and spread of cancer cells.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to the rise in prevalence of chronic diseases and disorders among population. The region's well-developed healthcare infrastructure, well-known companies, attractive reimbursement rules, and strong use in the cancer sector are all credited with this expansion. Furthermore, regulating organizations like the Food and Drug Administration (FDA) of the United States are essential in guaranteeing the security and caliber of sterile injectable medications in the area.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to the increasing prevalence of cancer cases among people and surging investment by government with the purpose of enhancing healthcare sector. In healthcare settings, sterile injectables are essential for administering a range of treatments, such as specialized medications, vaccinations, and antibiotics. Sterile injectable medications are often manufactured and distributed in the region by major pharmaceutical businesses, both domestic and foreign.

Key players in the market:

Some of the key players in Sterile Injectable market include Novartis AG, Baxter International Inc., Merck & Co., Inc, AstraZeneca plc, Johnson & Johnson Services, Inc, Gilead Sciences, Inc., JHP Pharmaceuticals, Pfizer Inc., Fresenius Kabi Ag, CordenPharma, Hikma Pharmaceuticals PLC, Bryllon LLC, Aenova Holding GmbH, Vetter Pharma-Fertigung GmbH & Co. KG and Catalent Pharma Solutions.

Key Developments:

In November 2023, AstraZeneca announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases.

In January 2022, Johnson & Johnson Medical Devices Companies announced that it will collaborate with Microsoft to further enable and expand JJMDC's secure and compliant digital surgery ecosystem.

In January 2021, Novartis announced collaboration with Alnylam to leverage Alnylam's proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research, potentially leading to development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.

Drug Types Covered:

  • Cytokines
  • Monoclonal Antibodies
  • Insulin
  • Peptide Hormones
  • Blood Factors
  • Vaccines
  • Immunoglobulins
  • Peptide Antibiotics
  • Other Drug Types

Molecule Types Covered:

  • Large Molecules
  • Small Molecules

Route of Administrations Covered:

  • Intravenous (IV)
  • Intramuscular (IM)
  • Subcutaneous (SC)

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Applications Covered:

  • Cardiovascular Diseases
  • Musculoskeletal
  • Cancer
  • Infections
  • Diabetes
  • Central Nervous Systems
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Sterile Injectable Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Cytokines
  • 5.3 Monoclonal Antibodies
  • 5.4 Insulin
  • 5.5 Peptide Hormones
  • 5.6 Blood Factors
  • 5.7 Vaccines
  • 5.8 Immunoglobulins
  • 5.9 Peptide Antibiotics
  • 5.10 Other Drug Types

6 Global Sterile Injectable Market, By Molecule Type

  • 6.1 Introduction
  • 6.2 Large Molecules
  • 6.3 Small Molecules

7 Global Sterile Injectable Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Intravenous (IV)
  • 7.3 Intramuscular (IM)
  • 7.4 Subcutaneous (SC)

8 Global Sterile Injectable Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies

9 Global Sterile Injectable Market, By Application

  • 9.1 Introduction
  • 9.2 Cardiovascular Diseases
  • 9.3 Musculoskeletal
  • 9.4 Cancer
  • 9.5 Infections
  • 9.6 Diabetes
  • 9.7 Central Nervous Systems
  • 9.8 Other Applications

10 Global Sterile Injectable Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Novartis AG
  • 12.2 Baxter International Inc.
  • 12.3 Merck & Co., Inc
  • 12.4 AstraZeneca plc
  • 12.5 Johnson & Johnson Services, Inc
  • 12.6 Gilead Sciences, Inc.
  • 12.7 JHP Pharmaceuticals
  • 12.8 Pfizer Inc.
  • 12.9 Fresenius Kabi Ag
  • 12.10 CordenPharma
  • 12.11 Hikma Pharmaceuticals PLC
  • 12.12 Bryllon LLC
  • 12.13 Aenova Holding GmbH
  • 12.14 Vetter Pharma-Fertigung GmbH & Co. KG
  • 12.15 Catalent Pharma Solutions

List of Tables

  • Table 1 Global Sterile Injectable Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Sterile Injectable Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 3 Global Sterile Injectable Market Outlook, By Cytokines (2021-2030) ($MN)
  • Table 4 Global Sterile Injectable Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 5 Global Sterile Injectable Market Outlook, By Insulin (2021-2030) ($MN)
  • Table 6 Global Sterile Injectable Market Outlook, By Peptide Hormones (2021-2030) ($MN)
  • Table 7 Global Sterile Injectable Market Outlook, By Blood Factors (2021-2030) ($MN)
  • Table 8 Global Sterile Injectable Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 9 Global Sterile Injectable Market Outlook, By Immunoglobulins (2021-2030) ($MN)
  • Table 10 Global Sterile Injectable Market Outlook, By Peptide Antibiotics (2021-2030) ($MN)
  • Table 11 Global Sterile Injectable Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 12 Global Sterile Injectable Market Outlook, By Molecule Type (2021-2030) ($MN)
  • Table 13 Global Sterile Injectable Market Outlook, By Large Molecules (2021-2030) ($MN)
  • Table 14 Global Sterile Injectable Market Outlook, By Small Molecules (2021-2030) ($MN)
  • Table 15 Global Sterile Injectable Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 16 Global Sterile Injectable Market Outlook, By Intravenous (IV) (2021-2030) ($MN)
  • Table 17 Global Sterile Injectable Market Outlook, By Intramuscular (IM) (2021-2030) ($MN)
  • Table 18 Global Sterile Injectable Market Outlook, By Subcutaneous (SC) (2021-2030) ($MN)
  • Table 19 Global Sterile Injectable Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 20 Global Sterile Injectable Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 21 Global Sterile Injectable Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 22 Global Sterile Injectable Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 23 Global Sterile Injectable Market Outlook, By Application (2021-2030) ($MN)
  • Table 24 Global Sterile Injectable Market Outlook, By Cardiovascular Diseases (2021-2030) ($MN)
  • Table 25 Global Sterile Injectable Market Outlook, By Musculoskeletal (2021-2030) ($MN)
  • Table 26 Global Sterile Injectable Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 27 Global Sterile Injectable Market Outlook, By Infections (2021-2030) ($MN)
  • Table 28 Global Sterile Injectable Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 29 Global Sterile Injectable Market Outlook, By Central Nervous Systems (2021-2030) ($MN)
  • Table 30 Global Sterile Injectable Market Outlook, By Other Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.